A matrix metalloproteinase inhibitor, ONO-4817, retards the development of mammary tumor and the progression of uterine adenomyosis in mice

Anticancer Research

Volumn 22, Issue 6 C, 2002, Pages 3985-3988

  Mori, Takao ^a   Nakahashi, Keiko ^a   Kyokuwa, Miho ^a   Yamasaki, Shinichi ^b   Nagasawa, Hiroshi ^c  

^a UNIVERSITY OF TOKYO   (Japan)

^b ONO PHARMACEUTICAL CO   (Japan)

^c MEIJI UNIVERSITY   (Japan)

Author keywords

Mammary tumor; Mice; MMP inhibitor; Uterine adenomyosis

Indexed keywords

5 ETHOXYMETHOXY N HYDROXY 2 METHYL 4 (4 PHENOXYBENZAMIDO)PENTANAMIDE; MATRIX METALLOPROTEINASE INHIBITOR; N HYDROXY 5 ETHOXYMETHYLOXY 2 METHYL 4 (4 PHENOXYBENZOYL)AMINOPENTANAMIDE; UNCLASSIFIED DRUG;

ADENOMYOSIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST TUMOR; CANCER INVASION; CONTROLLED STUDY; DRUG EFFECT; ENDOMETRIUM CELL; ENZYME DEGRADATION; ENZYME INHIBITION; EXTRACELLULAR MATRIX; GROWTH INHIBITION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEOGLYCAN SYNTHESIS; STRAIN DIFFERENCE; TUMOR GROWTH; TUMOR RECURRENCE;

ANIMALS; ANTICARCINOGENIC AGENTS; ENDOMETRIOSIS; ENDOMETRIUM; ENZYME INHIBITORS; FEMALE; MAMMARY NEOPLASMS, EXPERIMENTAL; MATRIX METALLOPROTEINASES; MICE; PHENYL ETHERS; UTERINE DISEASES;

EID: 0036875842     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (11)

1. Yamada A, Uegaki A, Nakamura T and Ogawa K: ONO-4817, an orally active matrix metalloproteinase inhibitor, prevents lipopolysaccharide-induced proteoglycan release from the joint cartilage in guinea pigs. Inflammation Res 49: 144-146, 2000.
2. Mori T, Yamasaki S, Masui S, Matsuda M, Sasabe H and Zhou Y-F: Suppression of the development of experimentally induced uterine adenomyosis by a novel matrix metalloproteinase inhibitor, ONO4817, in mice. Exp Biol Med 226: 429-433, 2001.
3. Khokha R and Denhardt DT: Matrix metalloproteinases and tissue inhibitor of metalloproteinases: A review of their role in tumorigenesis and tissue invasion. Invasion Metastasis 9: 391-405, 1989.
4. Nagasawa H, Yanai R, Taniguchi H, Tokuzen R and Nakahara W: Two-way selection of a stock of Swiss albino mice for mammary tumorigenesis: Establishment of two new strains (SHN and SLN). J Natl Cancer Inst 57: 425-430, 1976.
5. Mori T and Nagasawa H: Multiple endocrine syndrome in SHN mice: Mammary tumors and uterine adenomyosis. In: Comparative Aspects of Tumor Development (Kaiser HE, ed). Dordrecht, Kluwer Acad Pub, 1989, pp 121-130.
6. Mori T, Nagasawa H and Ohta Y: Prolactin and uterine adenomyosis in mice. In: Prolactin and Lesions in Breast, Uterus and Prostate (Nagasawa H, ed). Boca Raton, CRC Press, 1989, pp 123-139.
7. Snedecor GW and Cochran WG: Statistical Methods, 7th ed. Iowa State Univ Press, 1980, p 255.
8. McKay DG: A review of the status of endometrial cancer. Cancer Res 25: 1182-1192, 1965.
9. Nagasawa H and Yanai R: Normal and abnormal growth of mammary glands. In: Physiology of Mammary Glands (Yokoyama A, Mizuno H and Nagasawa H, eds). Baltimore, Univ. Park Press, 1978, pp 121-159.
10. Wolf C, Router N, Lutz Y et al: Stromelysin 3 belongs to a subgroup of proteinases expressed in breast carcinoma fibroblastic cells and possibly implicated in tumor progression. Proc Natl Acad Sci USA 90: 1843-1847, 1993.
11. Matsuda M, Sasabe H, Adachi Y, Suzuki T and Mori T: Increased invasion activity of endometrial stromal cell and elevated expression of matrix metalloproteinase messenger RNA in the uterine tissues of mice with experimentally induced adenomyosis. Am J Obset Gynecol 185: 1374-1380, 2001.